- NCIt
- C7185
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (130)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | completed | Phase 2 | 102 | CelgeneINDUSTRY | 6 | Oct 30, 2019 | clinicaltrials |
| NCT03746223 |
| Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma |
| unknown |
| Phase 2 |
| 42 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Oct 9, 2019 |
| clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT04066920 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | unknown | Phase 2 | 30 | Deok-Hwan YangOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01676831 | Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 / Phase 2 | 13 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02669511 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | completed | Phase 2 | 21 | PIQUR Therapeutics AGINDUSTRY | 0 | Jul 9, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | terminated | Phase 2 | 15 | Cell Medica LtdINDUSTRY | 4 | Mar 13, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03776279 | A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma | unknown | Phase 2 | 106 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT00038025 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02542124 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | unknown | Phase 2 | 10 | Neumedicines Inc.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | PIQUR Therapeutics AGINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00038376 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03701022 | PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 2 | 61 | Peking UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT03598959 | Tofacitinib Combined With Chidamide in R/R ENKTCL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00119392 | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 42 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 2 | 14 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00961220 | O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT02533323 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | terminated | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study(CHEMO-T) | unknown | Phase 2 | 87 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00253630 | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2018 | clinicaltrials |
| NCT03392714 | Bendamustine-based Combination Therapy for PCNSL | unknown | Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT02560441 | Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | unknown | Phase 2 | — | Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02825147 | Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma | completed | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03154918 | GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma | unknown | Phase 2 | 60 | Sichuan UniversityOTHER | 1 | Nov 8, 2017 | clinicaltrials |
| NCT01611259 | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue | completed | Phase 2 | 50 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02301364 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01682044 | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02276248 | Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma | completed | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT02423291 | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL(FIL_SGN01) | completed | Phase 2 | 15 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2019source: clinicaltrials